Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
mi
from
Vienna,
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
mi
from
Vienna,
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
mi
from
Washington, D.C.,
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Lexington, KY
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Louisville, KY
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Detroit, MI
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
New Brunswick, NJ
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
New York, NY
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Portland, OR
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Houston, TX
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
Computational Approach to Personalized Anemia Management
Status: Enrolling
Updated:  10/24/2017
University of Louisville, University Kidney Center
mi
from
Louisville, KY
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
Computational Approach to Personalized Anemia Management
Status: Enrolling
Updated: 10/24/2017
University of Louisville, University Kidney Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
Computational Approach to Personalized Anemia Management
Status: Enrolling
Updated:  10/24/2017
Western New England Renal & Transplant Associates, PC
mi
from
Springfield, MA
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
Computational Approach to Personalized Anemia Management
Status: Enrolling
Updated: 10/24/2017
Western New England Renal & Transplant Associates, PC
mi
from
Springfield, MA
Click here to add this to my saved trials
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
Computational Approach to Personalized Anemia Management
Status: Enrolling
Updated:  10/24/2017
Duke University
mi
from
Durham, NC
Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease
Computational Approach to Personalized Anemia Management
Status: Enrolling
Updated: 10/24/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
University of Alabama
mi
from
Birmingham, AL
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Children's Hospital Oakland
mi
from
Oakland, CA
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Colorado Sickle Cell Treatement and Research Center
mi
from
Aurora, CO
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Colorado Sickle Cell Treatement and Research Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Howard University Hospital
mi
from
Washington, D.C.,
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Howard University Hospital
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Johns Hopkins University
mi
from
Baltimore, MD
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Children's Hospital Boston
mi
from
Boston, MA
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Case-Western Reserve University Hospital
mi
from
Cleveland, OH
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Case-Western Reserve University Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated:  10/25/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Status: Enrolling
Updated: 10/25/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Microvessels and Heart Problems in Sickle Cell Disease
Microvascular and Cardiac Dysfunction in Sickle Cell Disease
Status: Enrolling
Updated:  10/26/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Microvessels and Heart Problems in Sickle Cell Disease
Microvascular and Cardiac Dysfunction in Sickle Cell Disease
Status: Enrolling
Updated: 10/26/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Emory University
mi
from
Atlanta, GA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Kentucky
mi
from
Lexington, KY
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Tulane University
mi
from
New Orleans, LA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Cornell University
mi
from
New York, NY
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Oregon
mi
from
Portland, OR
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Oregon
mi
from
Portland, OR
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Hemophilia Center of Western Pennsylvania
mi
from
Pittsburgh, PA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Hemophilia Center of Western Pennsylvania
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
North Texas Comprehensive Hemophilia Center
mi
from
Dallas, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
North Texas Comprehensive Hemophilia Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Baylor College of Medicine
mi
from
Houston, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Intermountain Hemophilia and Thrombosis Center
mi
from
Salt Lake City, UT
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Intermountain Hemophilia and Thrombosis Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Medical University of Vienna
mi
from
Vienna,
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Medical University of Vienna
mi
from
Vienna,
Click here to add this to my saved trials
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From HLA-Compatible Unrelated Donors in Severe Aplastic Anemia
Status: Enrolling
Updated:  11/10/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From HLA-Compatible Unrelated Donors in Severe Aplastic Anemia
Status: Enrolling
Updated: 11/10/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Arizona Oncology Associates, P.C.,
mi
from
Phoenix, AZ
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Arizona Oncology Associates, P.C.,
mi
from
Phoenix, AZ
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Pacific Cancer Medical Inc.
mi
from
Anaheim, CA
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Pacific Cancer Medical Inc.
mi
from
Anaheim, CA
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Compassionate Cancer Care Medical Group, Inc
mi
from
Fountain Valley, CA
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Compassionate Cancer Care Medical Group, Inc
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Saint Jude Heritage Medical Center
mi
from
Fullerton, CA
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Saint Jude Heritage Medical Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Loma Linda University Cancer Institute
mi
from
Loma Linda, CA
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Loma Linda University Cancer Institute
mi
from
Loma Linda, CA
Click here to add this to my saved trials